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OBJECTIVES The impact of infection-associated antiphospholipid antibodies (APA) on endothelial cell
activation, blood coagulation and fibrinolysis was evaluated in patients with infective
endocarditis with and without major embolic events.
BACKGROUND An embolic event is a common and severe complication of infective endocarditis. Despite the
fact that APAs are known to be associated with infectious diseases, their pathogenic role in
infective endocarditis has not been clearly defined.
METHODS The relationship among the occurrence of major embolic events, echocardiographic vegeta-
tion size, endothelial cell activation, thrombin generation, fibrinolysis and APA was examined
in 91 patients with definite infective endocarditis, including 26 patients with embolic events
and 65 control subjects without embolic events.
RESULTS Overall, 14.3% of patients exhibited elevated APA levels. Embolic events occurred more
frequently in patients with elevated levels of APA than in patients without (61.5% vs. 23.1%;
p 5 0.008). Patients with elevated levels of APA showed higher levels of prothrombin-
fragment F112 (p 5 0.005), plasminogen-activator inhibitor 1 (p 5 0.0002), von Willebrand
factor (p 5 0.002) and lower levels of activated protein C (p 5 0.001) than patients with
normal levels of APA. Thrombin generation and endothelial cell activation were both
positively correlated with levels of APA. The occurrence of elevated APA levels was
frequently associated with structural valve abnormalities (p 5 0.01) and vegetations .1.3 cm
(p 5 0.002).
CONCLUSIONS Infection-associated elevated APA levels in patients with infective endocarditis are related to
endothelial cell activation, thrombin generation and impairment of fibrinolysis. This may
contribute to the increased risk for major embolic events in these patients. (J Am Coll
Cardiol 1999;33:1365–71) © 1999 by the American College of Cardiology
Embolic events in infective endocarditis remain a common
and severe complication. They occur in 20% to 43% of cases,
with the majority as cerebral emboli (1–3). Several studies
report that the occurrence of embolic events is associated
with a higher mortality in patients with infective endocar-
ditis (4,5). During the last decade, the frequency of embolic
events in infective endocarditis reported in the literature
remains constant, despite improved antibiotic regimens and
a tendency toward earlier surgical intervention (4,6,7). In
infective endocarditis, it is believed that emboli are caused
by fragmentation of valvular vegetations as a result of
turbulent blood flow within the left-sided cardiac chambers
(8). Hence, several transthoracic and transesophageal echo-
cardiographic studies have attempted to correlate the occur-
rence of an embolic event in infective endocarditis with the
morphologic appearance of a valvular vegetation (9–11).
However, results of such studies have been inconsistent.
Several echocardiographic studies were unable to identify
any specific vegetation-derived parameter that could be
prospectively correlated with subsequent embolic events
(12–14).
Several recent investigations have demonstrated that
systemic bacterial infections, even in the absence of cardiac
involvement, represent an independent risk factor for an
embolic event (15–17). Inflammation-induced procoagulant
changes and endothelial cell activation appear to play a
major role in this setting. Evidence has been reported
showing that the development of infection-related an-
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tiphospholipid antibodies (APA) (e.g., independent from
the primary antiphospholipid-antibody syndrome or a de-
finable autoimmune disease) may have an impact on the
occurrence of embolic events (17–19). The interrelation-
ships between the presence of APA, alterations in platelet
activation, coagulation pathways and the occurrence of
embolic events have not been previously investigated in a
large patient population with definite infective endocarditis.
Of importance, infective endocarditis differs from other
infectious diseases owing to the presence of cardiac vegeta-
tions that represent an additional independent risk factor for
an embolic event.
Hence, the purpose of this study was to evaluate the
hypothesis that the development of infection-related APA
represents a major risk factor for embolic events in endo-
carditis, and such APAs are associated with in vitro endo-
thelial cell activation and procoagulant abnormalities.
METHODS
Patients. The study group consisted of 91 patients with
definite infective endocarditis according to the Duke criteria
(20). They were selected out of 215 consecutive patients
with suspected infective endocarditis who were referred to
our hospital between November 1991 and January 1997.
Morphologic findings were obtained in 45 patients during
heart surgery and in 5 patients during autopsy; in these
patients the diagnosis of infective endocarditis was con-
firmed by pathologic findings. In 41 patients the diagnosis
was made on the basis of clinical criteria (two major criteria:
n 5 32; one major and three minor criteria: n 5 9).
Twenty-six patients were diagnosed as having either a
cerebral (n 5 22) or major peripheral (n 5 4; 2 popliteal
artery, 1 femoral artery, 1 subclavian artery) embolic event.
In 9 patients, the embolic event occurred before admittance
to the hospital (#2 days) and in 17 patients after hospital
admittance (#2 days). Sixty-five patients with infective
endocarditis but without embolic events served as the
control group. The diagnosis of an embolic event was based
on physical examination, a cerebral computed tomographic
scan, a peripheral Doppler-ultrasonographic investigation
or an angiography. The diagnosis of a cerebral embolic
event was in all cases made by an experienced neurologist
who otherwise was not involved in this study. Patients with
a cerebral hemorrhage or an uncertainty about the diagnosis
of an embolic event were not included in the study.
All patients underwent transthoracic and transesophageal
echocardiography during the acute phase of infective endo-
carditis (,3 days of admission). In all patients the presence
of antiphospholipid-antibodies (e.g., LAC [lupus anticoag-
ulant] and/or ACA [anticardiolipin antibodies]) and de-
tailed coagulation system parameters were evaluated. Blood
samples were taken within the first three days after admit-
tance to the hospital. None of the patients had a history of
the primary antiphospholipid-antibody syndrome or an
autoimmune disease prior to acute infective endocarditis.
There were 48 men and 43 women, with a mean age of
54 6 15 years (range: 21 to 76 years). Patients being treated
with anticoagulants or with prosthetic valve devices were
excluded from the study group to avoid confounding by
anticoagulation treatment. After discharge from hospital, all
patients were followed regularly at the outpatient clinic at
12-month intervals for a maximum of 24 months. Mean
follow-up was 12 6 11 months.
Echocardiography. Transthoracic and transesophageal
echocardiographic examinations were performed with com-
mercially available ultrasound units (Hewlett-Packard So-
nos 1500, Bo¨eblingen, Germany; Vingmed CFM 800C,
Wiesbaden, Germany). For transthoracic studies, 2.5-MHz
transducers were used. A 5-MHz phased array transducer or
mechanical sector scanner was used for multiplane trans-
esophageal studies. The transesophageal examinations were
performed in the left lateral decubitus position after obtain-
ing patient’s informed consent and after a 6-h fasting
period. Before the probe was introduced into the esophagus
a local pharyngeal anesthetic was administered. Sedation
was routinely achieved with diazepam (2.5 to 10 mg IV). All
investigations were carried out without any complications.
The presence of structural valve abnormalities and vege-
tations were evaluated according to transesophageal echo-
cardiography by two independent investigators blinded as to
the clinical diagnosis. The localization and maximal diam-
eter of the vegetations were determined. A valvular vegeta-
tion was defined as an oscillating or fixed mass adherent to
a leaflet, distinct in echogenic structure and with motion
independent from the remainder of the involved leaflet. To
be called a vegetation, the lesion had to be detectable
throughout the complete cardiac cycle and to be visible in
multiple views. Diffuse valvular irregularities or valvular
thickening were not regarded as a vegetation (10,21).
Interobserver and intraobserver variabilities for measure-
ments of vegetation size were 7.8% and 5.4%, respectively.
A structural valve abnormality was defined as the presence
of valve sclerosis, stenosis, prolapse, aneurysm or perfora-
tion, with the specific diagnosis ascertained by previously
described criteria (22,23).
Abbreviations and Acronyms
ACA 5 anticardiolipin antibodies
APA 5 antiphospholipid antibodies
APA(1) 5 elevated levels of antiphospholipid
antibodies
APA(2) 5 normal levels of antiphospholipid antibodies
aPC 5 activated protein C
aPTT 5 activated prothrombin time
F112 5 prothrombin fragment 112
LAC 5 lupus anticoagulant
PAI-1 5 plasminogen activator inhibitor-1
SD 5 standard deviation
vWF 5 von Willebrand factor
1366 Kupferwasser et al. JACC Vol. 33, No. 5, 1999
Antiphospholipid Antibodies in Infective Endocarditis April 1999:1365–71
Laboratory tests. Blood samples were obtained between
8 AM and 10 AM by antecubital venipuncture with a
21-gauge needle. Blood was used only when venous return
was prompt throughout. The first 1 ml of blood was
discarded. Venous blood samples were collected into tubes
containing 3.8% trisodium citrate (ratio 9:1). The samples
were centrifuged for 20 min at 2000g at 4–8°C. Platelet-
poor plasma was divided into small aliquots in plastic tubes
and stored at 280°C until further evaluation.
Diagnosis of LAC was established according to the
recommended criteria (24): i) prolongation of a
phospholipid-dependent clotting test (commercially avail-
able aPTT [activated prothrombin time] method; Actin
FSL, Dade Behring, Frankfurt, Germany); ii) persistent
prolongation of the aPTT after mixing the test plasma with
normal pooled plasma; iii) modification of the clotting time
according to various phospholipid concentrations (Lupus
Anticoagulant Test, Baxter-Immuno, Vienna, Austria).
LAC was additionally assayed by the use of hexagonal H
(II) phase phospholipid molecules (Staclot LA, Stago,
Mannheim, Germany) and an ELISA test to determine
antiphospholipid IgG antibodies (Asserachrom APA IgG,
Stago, Mannheim, Germany). Values were expressed as
IgG-antiphospholipid (GPL)-units and considered nega-
tive at ,5 U/ml. The ACAs were assayed with a commer-
cially available ELISA (Varelisa Cardiolipin-Ab IgG,
Mannheim, Germany). Values were expressed as GPL-
units and considered negative at ,12 U/ml.
Prothrombin fragment 112 (F112), a marker of throm-
bin generation, was analyzed by ELISA (Enzygnost, F112,
Behring). The von Willebrand factor (vWF), a specific
marker for endothelial cell injury, was measured by ELISA
(Asserachrom vWF, Stago, Mannheim, Germany) with
values expressed as percent of those obtained with normal
pooled plasma. Plasminogen activator inhibitor-1 (PAI-1)
is regarded as a major determinant of fibrinolytic activity
(25). It also represents a function of endothelial release and
activation, although platelet granules also contain PAI-1,
which may complicate plasma measures (26). Activated
protein C (aPC) represents a marker of fibrinolysis. It is a
potent endogenous anticoagulant and an inhibitor of PAI-1
(27). Both aPC (Berichrom, Behring, Frankfurt, Germany)
and PAI-1 (Berichrom, Behring) were assayed by chromo-
genic substrate assays. All assays had a day-to-day variation
and an intra-assay coefficient of variation of ,12% and
,7%, respectively.
Statistics. Differences in the frequency of embolic events,
structural valve abnormalities and endocarditis-related valve
involvement in relation to the presence or absence of
elevated APA levels were analyzed by the Fisher exact test.
Mean values and the standard deviation (SD) were calcu-
lated for continuous variables. Differences between data of
multiple groups were analyzed by the Kruskal-Wallis non-
parametric one-way analysis of variance (ANOVA) test
with the Dunn’s multiple comparison post hoc test. The
nonparametric Mann-Whitney U test was used to test for
differences between data from the two groups. Correlations
between coagulation or fibrinolytic parameters were exam-
ined by linear regression and Spearman’s rank correlation
analysis. A p-value ,0.05 was considered to be significant.
RESULTS
Presence of antiphospholipid antibodies, correlation to
embolic events and follow-up. In 13/91 (14.3%) patients,
elevated APA levels were found. Elevated ACA levels only
were present in 10/91 (11%) patients. Elevated LAC and
ACA levels were present in 3/91 (3.3%) patients. In 78/91
(85.7%) patients, no elevated APA levels were found.
Embolic events occurred in APA(1) (elevated levels of
APA) and APA(2) (normal levels of APA) patients in 8/13
(61.5%) and 18/78 (23.1%), respectively (p 5 0.008). All
patients in whom LAC was present suffered from an
embolic event.
Twelve months after acute infective endocarditis, APAs
were still present in 3/10 (30%) and after 24 months in 1/7
(14%) of the initially APA(1) patients. Lupus anticoagu-
lant was not present in any of the three patients after 12
months. In parallel, no pathologic values for coagulation or
fibrinolytic parameters were found during follow-up when
normal APA levels were present in initially APA(1) pa-
tients. In terms of relapses of infective endocarditis within
24 months after hospital discharge, no significant differ-
ences occurred between APA(2) patients (no relapse) and
APA(1) patients (1/32; 3%; p 5 NS).
Valvular morphology and vegetation size. Among the 26
patients with embolic events, significantly larger vegetations
were observed in the presence of elevated APA levels (1.6 6
0.4 cm) as compared to patients with normal levels of APA
(1.1 6 0.4 cm) (p 5 0.002). Using a vegetation size of
1.3 cm as an arbitrary cutoff value, patients with elevated
APA levels revealed substantial differences in the frequency
of embolic events (p 5 0.002). In contrast, lesser differences
in the frequency of embolic events were found in APA(2)
Figure 1. Frequency of embolic events in four different groups of
patients according to vegetation size and presence of APA (*p ,
0.05).
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patients at this cutoff value (Fig. 1). In APA(1) patients,
the mitral valve was involved in 9/13 (69%), whereas in
APA(2) patients, this valve was involved in 32/78 (41%;
p 5 NS). No significant differences occurred between
APA(1) and APA(2) patients in the mean number of
vegetations per valve (1.2 6 0.4 vs. 1.3 6 0.5; p 5 NS) and
in the number of multiple valve endocarditis (8% vs. 6%;
p 5 NS). Infective endocarditis was accompanied by a
significantly higher amount of structural valve abnormalities
in APA(1) patients (7/13; 54%) than in APA(2) patients
(15/78; 19%) (p 5 0.01) (Table 1).
Relationship between antiphospholipid antibodies, en-
dothelial activation and thrombin generation. In 7/8
(88%) APA(1) patients with embolic events, elevated
F112 levels were found. Among APA(2) patients with
embolic events 10/18 (56%) revealed elevated F112 levels.
Among the controls, 23 patients (35%) revealed elevated
F112 levels. The highest F112 levels were present in
APA(1) patients with embolic events (p 5 0.005) (Fig. 2).
Patients with embolic events revealed significantly higher
PAI-1 levels (15.6 6 4.1 IU/ml) when elevated APAs were
present, as compared to patients with normal levels of APA
(7.2 6 4.6 IU/ml) (p 5 0.0002) (Fig. 3). In contrast, the
mean level of PAI-1 in patients without embolic events was
3.8 6 1.4 IU/ml with only minor differences between
APA(2) and APA(1) patients. In the patients with em-
bolic events, PAI-1 levels were positively correlated to APA
levels (r 5 0.7; p , 0.0001).
In patients with embolic events, vWF levels were signif-
icantly higher in APA(1) patients than in APA(2) patients
(228 6 62% vs. 153 6 29%; p 5 0.002) (Fig. 4). Controls
revealed mean vWF levels of 145 6 30%, with only slight
differences between APA(2) and APA(1) patients. Levels
of vWF were positively correlated to levels of APA (r 5
0.66; p 5 0.0002).
Relationship between antiphospholipid antibodies and
fibrinolysis. Mean circulating aPC levels were lowest in
APA(1) patients with embolic events (p 5 0.001) (Fig. 5).
No substantial differences occurred between patients in
whom aPC was evaluated before or after the embolic event.
Table 1. Frequency of Structural Valve Abnormalities in
Patients With Normal and Elevated Levels of APA
APA(1) (n 5 13) APA(2) (n 5 78)
Sclerosis 2 (15%) 5 (6%)
Stenosis 0 2 (3%)
Leaflet-prolapse 3 (23%) 5 (6%)
Leaflet-aneurysm 1 (7%) 1 (1%)
Leaflet-perforation 3 (23%) 3 (4%)
Numbers 5 frequency of structural valve abnormalities; a patient can be mentioned
more than once; numbers in brackets 5 frequency in percent of patients.
Figure 2. Mean F112 levels and standard deviations in patients
with embolic events and control subjects. (Upper range of normal
values 5 1.1 nM/l; nM/l 5 nmol per liter.)
Figure 3. PAI-1 levels in 26 patients with embolic events accord-
ing to normal and elevated anticardiolipin-antibody titers. A
majority of values in both patient groups exceed the normal range
of PAI-1. However, 2/18 (11%) and 6/8 (75%) of patients with
normal and elevated ACA titers have PAI-1 levels .15 UIU/ml,
respectively. (Upper range of normal values 5 3.5 UIU/ml; the
horizontal bars indicate the mean values in each patient group;
UIU 5 urokinase inhibiting units.)
Figure 4. The vWF levels in 26 patients with embolic events
according to normal and elevated anticardiolipin-antibody titers. A
majority of values in both patient groups exceed the normal range
of vWF. This is not surprising as vWF is an acute-phase reactant.
Nevertheless, 1/18 (6%) and 4/8 (50%) of patients with normal and
elevated ACA titers have vWF levels .200%, respectively. (Upper
range of normal values 5 150%.)
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In patients with embolic events, aPC was reduced in 75%
(6/8) and 13% (2/16) according to elevated and normal
APA levels, respectively. None of the APA(1) patients
without embolic events revealed reduced aPC levels. The
aPC levels were inversely related to APA levels (r 5 20.48;
p 5 0.01) in patients with embolic events.
DISCUSSION
Until now it has not been clear whether the presence of
infection-related APA adds to the underlying pro-
thrombotic state and impacts on the frequency of embolic
events in infective endocarditis. Therefore, it is important to
investigate the impact of APA on the clinical course of
patients with infective endocarditis, in which valvular veg-
etations already represent an independent risk factor for an
embolic event. The study provides three major findings: 1)
The presence of infection-related APA is significantly
associated with alterations of endothelial cells, coagulation-
pathway abnormalities and inhibition of fibrinolysis; 2)
infection-related APA can be divided in two groups, the
biologically active and the biologically inactive, with the
latter having no impact on endothelial cell activation or the
procoagulant state; and 3) the presence of infection-related
APA adds substantially to the risk of an embolic event in
infective endocarditis.
Previous literature. The APA react with negatively
charged phospholipids. They require beta-2-glycoprotein 1
as a cofactor to bind to phospholipids; beta-2-glycoprotein 1
inhibits factor Xa synthesis on activated platelets. Thus,
APA may interfere with this inhibition leading to factor Xa
generation and thrombin formation (28,29). Previous re-
ports demonstrated that immunoglobulin fractions from
patients with APA can bind to endothelial cells (30,31).
This results in endothelial cell activation and phenotypic
changes, with induction of a pro-adhesive, pro-thrombotic
surface causing a subsequent perturbation of the
endothelium-platelet axis and thrombin generation (32,33).
In an inflammatory state like infective endocarditis, the
activation of endothelial cells is induced by cytokines such as
TNF-alpha, interleukin-1 or bacterial endotoxins (34,35).
Recently it has been reported that LAC may bind to
heparan sulfate on endothelial cells. This interferes with the
antithrombin III–heparan downregulation of serine pro-
teases (36). The presence of LAC as described in autoim-
mune diseases or the primary antiphospholipid syndrome
causes interference with the coagulation pathway and leads
to an alteration of various enzymatic or cellular functions
linked to hemostasis. It appears to be associated with a
higher risk of thrombosis and embolic events (36,37).
Specific data about the development of APA in the
setting of definite infective endocarditis are scarce. It is well
known that APA occur frequently in infectious diseases
(19,38). However, most studies suggest that these infection-
induced APA have no pathogenic role and are not associ-
ated with LAC activity (39,40). Several recent reports
demonstrated that transitory APA in infectious diseases
seem to have a pathogenic role for venous thrombosis or
arterial embolization (41,42). In patients with infection-
associated stroke Macko et al. described a significantly lower
level of aPC, and a higher level of APA compared to
controls, suggesting an interference with the aPC activation
reaction, which has been described earlier in vitro
(32,43,44). In patients with stroke, Ameriso et al. (18)
reported elevated levels of d-dimer and ACA when an
infection occurred prior to the stroke.
Role of antiphospholipid antibodies in infective endo-
carditis. In our study, there were apparently two different
subsets of APA. In one subset (five patients) the APA did
not affect hemostasis and was not associated with an
increased frequency of embolic events. In the other subset
(eight patients) the presence of APA was associated with
endothelial cell activation, thrombin generation and reduced
fibrinolysis leading to a higher frequency of embolic events.
The lack of any symptoms compatible with the primary
antiphospholipid syndrome prior to the onset of infective
endocarditis, and the decline in APA titers after treatment
of infective endocarditis, strongly suggest that the APA
syndrome in infective endocarditis was acquired and was
infective endocarditis-related. However, data from this
study do not exclude the transitory development of APA
consequent to previous infectious diseases other than infec-
tive endocarditis. In this regard, it is conceivable that the
higher number of structural valve abnormalities and mitral
valve involvement in patients with elevated levels of APA
might be a result of preexisting APA. Previous studies
reported a correlation between the presence of APA and the
occurrence of valvular heart disease in autoimmune diseases
or the primary antiphospholipid syndrome (45,46).
Endothelial cell activation and thrombin generation as
assessed by vWF, PAI-1 and F112 levels were significantly
higher in APA(1) patients with embolic events. A previous
study demonstrated a close association between endothelial
cell activation and thrombin generation in a group of
patients with systemic lupus erythematosus and elevated
Figure 5. Mean aPC levels and standard deviations in patients
with embolic events and control subjects. (Upper range of normal
values 5 70%.)
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APA levels (33). However, PAI-1 is also released by
activated platelets, which have a direct impact on thrombin
generation. Therefore, platelet activation might play an
additional role in this setting. Intriguingly, endothelial cell
activation and consecutive thrombin formation is a common
finding in systemic infectious diseases as well as in certain
noninfectious diseases (47–50). Data of this study demon-
strate that endothelial cell activation and thrombin forma-
tion is a common finding also in acute infective endocarditis
even without elevated APA levels, suggesting the presence
of other APA-independent mechanisms for the activation
of the clotting system. It should be emphasized, however,
that the presence of APA in infective endocarditis adds to
this potential for thrombin generation by increased endo-
thelial cells activation, resulting in the highest thrombin
generation in this subset of patients.
Our data would also suggest that in these APA(1)
patients with infective endocarditis, elevated thrombin gen-
eration is associated with increased growth of vegetations.
In this context, vegetation size is a meaningful parameter to
identify individuals at high risk for an embolic event within
the group of APA(1) patients. Vegetation size in APA(2)
patients did not allow the accurate prediction of embolic
events in an individual patient, although embolic events
occurred more frequently in patients with vegetations larger
than 1.3 cm.
Antiphospholipid antibodies had an inhibitory effect on
fibrinolysis as seen by the inverse relationship between APA
and aPC levels. Data are strikingly similar to the study of
Macko et al. (43) in patients with infection-associated
stroke. Previous reports have shown that patients with
continuously decreased aPC levels are less likely to develop
clinical symptoms than patients with a transitory aPC
decline (51,52). Follow-up data of this study demonstrate
that pathologic aPC levels in APA(1) patients with acute
infective endocarditis appear to be transitory, therefore
increasing the likelihood for the clinical relevance of this
finding. In support of this notion, elevated APA levels in
the presence of acute infective endocarditis might indicate a
possible trigger mechanism for embolic events. It has
already been demonstrated that APA interfere with the
generation of aPC on the endothelial cell surface (44).
Activated protein C adds to fibrinolysis by inhibiting PAI-1
(43). Impaired fibrinolysis promotes increased fibrin gener-
ation in the subgroup of APA(1) patients with embolic
events, adding to a larger vegetation size.
Conclusions. Data of this study demonstrate that within
the group of APA(1) patients with definite infective
endocarditis a subset exists with a high risk for major
embolic events. The subset can be readily identified by
echocardiographic quantitation of vegetation size and by
evaluation of coagulation and fibrinolysis parameters. The
pathways involved in promoting the risk of embolization
include endothelial cell activation, elevated thrombin for-
mation and impaired fibrinolysis. The APA may trigger
embolic events by pertubing these pathways and enhancing
the growth of a vegetation, with subsequent fragmentation
from shear forces in the turbulent bloodstream. The iden-
tification of APA(1) patients with infective endocarditis as
being at high risk for embolization might influence the
decision algorithm for an early and preventive surgical
intervention to avoid the deleterious consequences of an
embolic event.
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